Function over Form: Addressing immunogenicity risk and other barriers to clinical development of non-conventional antibody therapeutics
19 Feb 2025
Formats & Scaffolds
- Is broad-based use of conventional IgG somewhat limited by its fundamental biophysical properties? Are alternative formats better for eliciting potent clinical responses for particular MOA such as receptor clustering, tissue penetration or crossing the BBB?
- How does the risk of anti-drug response pose a barrier for clinical development of therapeutics in alternative formats and scaffolds? Is this risk real?
- Are mini proteins and peptides underutilized in therapeutic designs?
